Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03030248 · ClinicalTrials.gov registry record · Phase 2
Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT03030248 is a Phase 2 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 9 participants.
The verdict
NCT03030248, a Phase 2 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study will randomized hematology oncology patients with active diarrhea and a NAAT positive/toxin EIA negative to either 14 days of oral vancomycin capsules or placebo. The study is designed to include 30 patients (15 per arm). Outcomes will include C. difficile load using qPCR, VRE loads, structural and functional microbiome changes and frequency of bowel movements. All endpoints will be measured at several time points including days 0, 14, 21 and 90.
Interventions
- DRUG Placebo Oral Capsule
- DRUG Vancomycin Oral Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2020-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03030248
The ClinicalTrials.gov registry entry for NCT03030248 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Capsule is the first listed.
NCT03030248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03030248 about?
NCT03030248 is a clinical study titled "Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients". This study will randomized hematology oncology patients with active diarrhea and a NAAT positive/toxin EIA negative to either 14 days of oral vancomycin capsules or placebo. The study is designed to include 30 patients (15 per arm). Outcomes will include C. difficile load using qPCR, VRE loads, str...
What is the current status of trial NCT03030248?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2018-06-01. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT03030248?
The interventions under investigation include: Placebo Oral Capsule (DRUG), Vancomycin Oral Capsule (DRUG).
Who is sponsoring clinical trial NCT03030248?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.